Abstract
The choice of dopaminergic therapy in early Parkinson disease (PD) is an important clinical decision, yet factors influencing this decision have not been extensively studied. We sought to investigate the factors that may be associated with the choice of dopaminergic therapy at the NINDS Exploratory Trials in PD (NET-PD) Long-Term Study-1 (LS1). NET-PD LS1 was a clinical trial of creatine versus placebo in participants with early, mild PD on stable doses of dopaminergic therapy. Baseline data from 1616 out of the 1741 participants were evaluated using univariable and multivariable logistic or generalized logit regression analyses for available factors associated with the choice of dopaminergic therapy. The dopaminergic therapy choice was determined as: (i) therapy that subjects recalled taking 180 days before the study; (ii) therapy at baseline; and (iii) the longest duration of therapy reported by participants. Younger age, higher education level, longer length of time since PD diagnosis and use of an adjunctive, non-dopaminergic or monoamine oxidase inhibitor medication were associated with more frequent use of dopamine agonist compared to levodopa or combination therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 74-81 |
| Number of pages | 8 |
| Journal | Journal of the Neurological Sciences |
| Volume | 366 |
| DOIs | |
| State | Published - Jul 15 2016 |
Fingerprint
Keywords
- Clinical trial
- Dopamine agonists
- Levodopa
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Cite this
Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America. / Goudreau, John L.; Pérez, Adriana; Aminoff, Michael J.; Boyd, James T.; Burau, Keith D.; Christine, Chadwick W.; Leehey, Maureen; Morgan, John C.
In: Journal of the Neurological Sciences, Vol. 366, 15.07.2016, p. 74-81.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America
AU - Goudreau, John L.
AU - Pérez, Adriana
AU - Aminoff, Michael J.
AU - Boyd, James T.
AU - Burau, Keith D.
AU - Christine, Chadwick W.
AU - Leehey, Maureen
AU - Morgan, John C.
PY - 2016/7/15
Y1 - 2016/7/15
N2 - The choice of dopaminergic therapy in early Parkinson disease (PD) is an important clinical decision, yet factors influencing this decision have not been extensively studied. We sought to investigate the factors that may be associated with the choice of dopaminergic therapy at the NINDS Exploratory Trials in PD (NET-PD) Long-Term Study-1 (LS1). NET-PD LS1 was a clinical trial of creatine versus placebo in participants with early, mild PD on stable doses of dopaminergic therapy. Baseline data from 1616 out of the 1741 participants were evaluated using univariable and multivariable logistic or generalized logit regression analyses for available factors associated with the choice of dopaminergic therapy. The dopaminergic therapy choice was determined as: (i) therapy that subjects recalled taking 180 days before the study; (ii) therapy at baseline; and (iii) the longest duration of therapy reported by participants. Younger age, higher education level, longer length of time since PD diagnosis and use of an adjunctive, non-dopaminergic or monoamine oxidase inhibitor medication were associated with more frequent use of dopamine agonist compared to levodopa or combination therapy.
AB - The choice of dopaminergic therapy in early Parkinson disease (PD) is an important clinical decision, yet factors influencing this decision have not been extensively studied. We sought to investigate the factors that may be associated with the choice of dopaminergic therapy at the NINDS Exploratory Trials in PD (NET-PD) Long-Term Study-1 (LS1). NET-PD LS1 was a clinical trial of creatine versus placebo in participants with early, mild PD on stable doses of dopaminergic therapy. Baseline data from 1616 out of the 1741 participants were evaluated using univariable and multivariable logistic or generalized logit regression analyses for available factors associated with the choice of dopaminergic therapy. The dopaminergic therapy choice was determined as: (i) therapy that subjects recalled taking 180 days before the study; (ii) therapy at baseline; and (iii) the longest duration of therapy reported by participants. Younger age, higher education level, longer length of time since PD diagnosis and use of an adjunctive, non-dopaminergic or monoamine oxidase inhibitor medication were associated with more frequent use of dopamine agonist compared to levodopa or combination therapy.
KW - Clinical trial
KW - Dopamine agonists
KW - Levodopa
UR - http://www.scopus.com/inward/record.url?scp=84968538122&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84968538122&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2016.04.021
DO - 10.1016/j.jns.2016.04.021
M3 - Article
C2 - 27288780
AN - SCOPUS:84968538122
VL - 366
SP - 74
EP - 81
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
SN - 0022-510X
ER -